AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21128876 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-substance-dependent, non-homeless)
Number of subjects: 20
Study 19150530 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 60
Study 19150530 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol
Number of subjects: 60
Study 19150530 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 60
Study 19150530 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 60
Study 16762992 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight adolescents
Number of subjects: 215
Study 16762992 — intervention group
Group type: EXPERIMENTAL
Intervention: At risk for overweight adolescents
Number of subjects: 215
Study 16762992 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight adolescents
Number of subjects: 215
Study 14725954 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-centered (CC) intervention
Number of subjects: 80
Study 14725954 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-school partnership (FSP) intervention
Number of subjects: 80
Study 14725954 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard educational setting)
Number of subjects: 80
Study 10873409 — intervention group
Group type: EXPERIMENTAL
Intervention: LEETZ followed by laser vaporization
Number of subjects: 426
Study 10873409 — intervention group
Group type: COMPARATOR
Intervention: LEETZ alone
Number of subjects: 426
Study 9279674 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac eyedrops
Number of subjects: 88
Study 9279674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 1650108 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial electric treatment (TET) using a combination of direct current and pulse current at a frequency of 70-80 Hz
Number of subjects: 0
Study 1650108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6406397 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-course pelvic irradiation (10 fractions of 250 rad each, total 5000 rad)
Number of subjects: 287
Study 6406397 — intervention group
Group type: COMPARATOR
Intervention: Continuous pelvic irradiation (30 fractions of 170 rad each, total 5100 rad)
Number of subjects: 287
Study 6406397 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups followed by intracavitary brachytherapy (3000 rad at point A) or external boost (1600 rad) if brachytherapy not possible
Number of subjects: 287
Study 6406397 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall tumor control at two years: 81% for Stage II-B, 67% for III-A, 53% for Stage III-B, 32% for Stage IV-A
Number of subjects: 287
Study 6406397 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall two-year survival: 70% for Stage II-B, 58% for III-A, 46% for III-B, 23% for IV-A
Number of subjects: 287
Study 31776362 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict volume control monitored by bioimpedance spectroscopy (BIS)
Number of subjects: 151
Study 31776362 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-averaged normohydration
Number of subjects: 151
Study 31776362 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-averaged overhydration (TA-OH/ECW)
Number of subjects: 151
Study 28318687 — intervention group
Group type: EXPERIMENTAL
Intervention: EVEN group (n=7)
Number of subjects: 14
Study 28318687 — intervention group
Group type: COMPARATOR
Intervention: UNEVEN group (n=7)
Number of subjects: 14
Study 26237453 — intervention group
Group type: EXPERIMENTAL
Intervention: PAPD plus SRP
Number of subjects: 24
Study 26237453 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment plus SRP
Number of subjects: 24
Study 22945709 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpositional flap (TF)
Number of subjects: 20
Study 22945709 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue graft (CTG)
Number of subjects: 20
Study 20299535 — intervention group
Group type: EXPERIMENTAL
Intervention: Wake up and breathe protocol (interrupts and reduces sedative exposure)
Number of subjects: 180
Study 20299535 — intervention group
Group type: EXPERIMENTAL
Intervention: Wake up and breathe protocol
Number of subjects: 180
Study 20299535 — intervention group
Group type: COMPARATOR
Intervention: Sedation per usual care plus daily SBTs (control)
Number of subjects: 180
Study 18413707 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic psychotherapy with transference interpretations
Number of subjects: 100
Study 18413707 — intervention group
Group type: COMPARATOR
Intervention: Dynamic psychotherapy without transference interpretations
Number of subjects: 100
Study 16080072 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline (100 mg followed by 50 mg intravenously twice daily)
Number of subjects: 1116
Study 16080072 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (1 g intravenously twice daily) plus Aztreonam (2 g intravenously twice daily)
Number of subjects: 1116
Study 16080072 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 1116
Study 16080072 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin-aztreonam
Number of subjects: 1116
Study 12439772 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training (six sets of six eccentric contractions at 120% of one maximal concentric repetition, performed four times a week for four weeks)
Number of subjects: 14
Study 12439772 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training
Number of subjects: 14
Study 10473957 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% retinaldehyde
Number of subjects: 0
Study 10473957 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 0
Study 8644912 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic bead antigen‐capture enzyme linked immunoassay (MBAC‐EIA)
Number of subjects: 0
Study 8644912 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger individuals (5‐14 years of age)
Number of subjects: 0
Study 8644912 — intervention group
Group type: COMPARATOR
Intervention: Older individuals (greater than 14 years of age)
Number of subjects: 0
Study 8644912 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 0
Study 1922662 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate treatment with Prednisone (Polfa) and Decaris (Richter)
Number of subjects: 18
Study 1922662 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (Polfa) exclusively
Number of subjects: 18
Study 6823476 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotation-advancement repairs
Number of subjects: 35
Study 6823476 — intervention group
Group type: COMPARATOR
Intervention: Triangular repairs
Number of subjects: 35
Study 31324233 — intervention group
Group type: EXPERIMENTAL
Intervention: Online HIV intervention services
Number of subjects: 1100
Study 29650208 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking and talking intervention
Number of subjects: 83
Study 29650208 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 83
Study 26903314 — intervention group
Group type: EXPERIMENTAL
Intervention: QAMS-containing acrylic disks
Number of subjects: 32
Study 26903314 — intervention group
Group type: COMPARATOR
Intervention: QAMS-free control disks
Number of subjects: 32
Study 25204091 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia readiness syndrome (ARS) group (N=23)
Number of subjects: 46
Study 25204091 — intervention group
Group type: COMPARATOR
Intervention: Control group (no signs of ARS) (N=23)
Number of subjects: 46
Study 23099809 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with 5‐FU/LEV
Number of subjects: 335
Study 23099809 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 335
Study 21057441 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP) with a short reperfusion phase (2 min)
Number of subjects: 40
Study 21057441 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ischemic preconditioning)
Number of subjects: 40
Study 21057441 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 21057441 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 17955458 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphisms in the CHRNA4 gene tested for interactions with prenatal smoking exposure
Number of subjects: 0
Study 17955458 — intervention group
Group type: COMPARATOR
Intervention: Previous interactions for the DRD4 and DAT1 genes with prenatal smoking exposure
Number of subjects: 0
Study 17653259 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosaptide (PRO) 2 mg/d
Number of subjects: 237
Study 17653259 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosaptide (PRO) 4 mg/d
Number of subjects: 237
Study 17653259 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosaptide (PRO) 8 mg/d
Number of subjects: 237
Study 17653259 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosaptide (PRO) 16 mg/d
Number of subjects: 237
Study 17653259 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 237
Study 15277146 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g c9,t11 CLA/d
Number of subjects: 25
Study 15277146 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 25
Study 11023084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin, 6 mg in a single dose
Number of subjects: 211
Study 11023084 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole, 400 mg/day for 3 days
Number of subjects: 211
Study 11023084 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrvinium pamoate, 5 mg/kg/day for 3 days
Number of subjects: 211
Study 9342643 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Alzheimer's disease
Number of subjects: 36
Study 9342643 — intervention group
Group type: COMPARATOR
Intervention: Age-matched control subjects
Number of subjects: 36
Study 1337525 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin (400 mg orally once daily)
Number of subjects: 126
Study 1337525 — intervention group
Group type: COMPARATOR
Intervention: TMP/SMX (160/800 mg orally twice daily)
Number of subjects: 126
Study 3159759 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% ketoconazole cream
Number of subjects: 37
Study 3159759 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 37
Study 31405377 — intervention group
Group type: EXPERIMENTAL
Intervention: LSIL, HSIL, CSCC
Number of subjects: 432
Study 31405377 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy females)
Number of subjects: 432
Study 29670895 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasses and Occlu-pad
Number of subjects: 46
Study 29670895 — intervention group
Group type: COMPARATOR
Intervention: Glasses only
Number of subjects: 46
Study 29670895 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlu-pad compliance
Number of subjects: 46
Study 29670895 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlu-pad training time
Number of subjects: 46
Study 29670895 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance rate comparison
Number of subjects: 46
Study 26259981 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 30
Study 26259981 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical management (IMM)
Number of subjects: 30
Study 25262435 — intervention group
Group type: EXPERIMENTAL
Intervention: Print-delivered basic (PB)
Number of subjects: 1729
Study 25262435 — intervention group
Group type: EXPERIMENTAL
Intervention: Print-delivered environmental (PE)
Number of subjects: 1729
Study 25262435 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based environmental (WE)
Number of subjects: 1729
Study 25262435 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 1729
Study 22241602 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 μg/kg
Number of subjects: 16
Study 22241602 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 10 μg/kg
Number of subjects: 16
Study 22241602 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 10 μg/kg and 40 μg/kg
Number of subjects: 16
Study 19849695 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Practitioner
Number of subjects: 160
Study 19849695 — intervention group
Group type: COMPARATOR
Intervention: Dermatologist
Number of subjects: 160
Study 17973851 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinucleotide repeats for carrier detection and prenatal diagnosis
Number of subjects: 85
Study 15386762 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy for women with recently diagnosed primary breast cancer
Number of subjects: 352
Study 12214257 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (anticipation of a blood test)
Number of subjects: 213
Study 12214257 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anticipation of a blood test)
Number of subjects: 213
Study 9527733 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone induction and isoflurane maintenance
Number of subjects: 157
Study 9527733 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone induction and isoflurane maintenance plus ondansetron 5 mg x m(‐2) i.v.
Number of subjects: 157
Study 9527733 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol induction and maintenance
Number of subjects: 157
Study 9527733 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol induction and maintenance plus lignocaine 2 mg x kg(‐1) i.v.
Number of subjects: 157
Study 9527733 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 157
Study 9527733 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 157
Study 7608323 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastatin 300 micrograms once daily
Number of subjects: 21
Study 7608323 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 21
Study 2515159 — intervention group
Group type: EXPERIMENTAL
Intervention: Daonil (product A)
Number of subjects: 16
Study 2515159 — intervention group
Group type: COMPARATOR
Intervention: Glucomid (product B)
Number of subjects: 16
Study 2515159 — intervention group
Group type: EXPERIMENTAL
Intervention: Both products
Number of subjects: 16
Study 194679 — intervention group
Group type: EXPERIMENTAL
Intervention: L phenylalanine mustard (L PAM)
Number of subjects: 100
Study 194679 — intervention group
Group type: EXPERIMENTAL
Intervention: L phenylalanine mustard (L PAM) plus 5 fluorouracil (5 FU)
Number of subjects: 100
Study 194679 — intervention group
Group type: COMPARATOR
Intervention: L PAM
Number of subjects: 100
Study 31779585 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV seroprevalence in 11-14 year olds (60.4%)
Number of subjects: 732
Study 31779585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnicity (other ethnicity versus white individuals)
Number of subjects: 732
Study 31779585 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 732
Study 30527256 — intervention group
Group type: EXPERIMENTAL
Intervention: Okinawan-based Nordic (O-BN) diet
Number of subjects: 19
Study 30527256 — intervention group
Group type: COMPARATOR
Intervention: Standard breakfast
Number of subjects: 19
Study 30527256 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-diabetic subjects)
Number of subjects: 19
Study 26699597 — intervention group
Group type: EXPERIMENTAL
Intervention: High-degree AV block
Number of subjects: 29677
Study 26699597 — intervention group
Group type: EXPERIMENTAL
Intervention: Asystole
Number of subjects: 29677
Study 26699597 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromechanical dissociation (EMD)
Number of subjects: 29677
Study 26699597 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker insertion
Number of subjects: 29677
Study 26699597 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with high-degree AV block
Number of subjects: 29677
Study 26699597 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with asystole or EMD
Number of subjects: 29677
Study 25179977 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 67
Study 22154118 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC-PH (4 cycles of FEC followed by 4 cycles of trastuzumab and 12 weekly doses of paclitaxel 80 mg/m(2))
Number of subjects: 102
Study 22154118 — intervention group
Group type: COMPARATOR
Intervention: FEC-DH (4 cycles of FEC followed by 4 cycles of trastuzumab and 4 cycles of docetaxel 75 mg/m(2))
Number of subjects: 102
Study 22154118 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC-PH in HR(-) tumors
Number of subjects: 102
Study 22154118 — intervention group
Group type: COMPARATOR
Intervention: FEC-DH in HR(-) tumors
Number of subjects: 102
Study 22154118 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC-PH in HR(+) tumors
Number of subjects: 102
Study 22154118 — intervention group
Group type: COMPARATOR
Intervention: FEC-DH in HR(+) tumors
Number of subjects: 102
Study 20706089 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 20
Study 20706089 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 17613598 — intervention group
Group type: EXPERIMENTAL
Intervention: New clinical classification system for MS (monofocal vs multifocal)
Number of subjects: 487
Study 16305563 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 80 mg/1.5 mL gel solution
Number of subjects: 60
Study 16305563 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol 400 mcg/1.5 mL gel solution
Number of subjects: 60
Study 16305563 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 60
Study 16305563 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol
Number of subjects: 60
Study 12819295 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with epoetin beta (NeoRecormon) administered subcutaneously aiming for a target Hb level of 13‐15 g/dl.
Number of subjects: 600
Study 12819295 — intervention group
Group type: COMPARATOR
Intervention: Late treatment with epoetin beta (NeoRecormon) administered subcutaneously starting once Hb level declines to below 10.5 g/dl (target Hb level 10.5‐11.5 g/dl).
Number of subjects: 600
Study 10395120 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (Losec) administered intravenously
Number of subjects: 0
Study 8905503 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed reminder
Number of subjects: 970
Study 8905503 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed reminder plus nurse counseling
Number of subjects: 970
Study 8905503 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 970
Study 1863026 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of bumetanide (12 mg over 12 hours)
Number of subjects: 8
Study 1863026 — intervention group
Group type: COMPARATOR
Intervention: Bolus therapy of bumetanide (two 6 mg doses separated by 6 hours)
Number of subjects: 8
Study 1863026 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of bumetanide
Number of subjects: 8
Study 1863026 — intervention group
Group type: COMPARATOR
Intervention: Bolus therapy of bumetanide
Number of subjects: 8
Study 6756931 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline infusion during placebo
Number of subjects: 8
Study 6756931 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline infusion during metoprolol medication
Number of subjects: 8
Study 6756931 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline infusion during acebutolol medication
Number of subjects: 8
Study 6756931 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 100 mg
Number of subjects: 8
Study 6756931 — intervention group
Group type: COMPARATOR
Intervention: Acebutolol 400 mg
Number of subjects: 8
Study 31772695 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT + self-ligating (SL) bracket
Number of subjects: 32
Study 31772695 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT + conventional (Conv.) bracket
Number of subjects: 32
Study 31772695 — intervention group
Group type: COMPARATOR
Intervention: non-LLLT + SL bracket
Number of subjects: 32
Study 31772695 — intervention group
Group type: COMPARATOR
Intervention: non-LLLT + Conv. bracket
Number of subjects: 32
Study 28973094 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 28
Study 28973094 — intervention group
Group type: EXPERIMENTAL
Intervention: abobotulinumtoxinA
Number of subjects: 28
Study 28973094 — intervention group
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA
Number of subjects: 28
Study 26028054 — intervention group
Group type: EXPERIMENTAL
Intervention: ToM training (ToM Strange Stories and ToM Animations)
Number of subjects: 127
Study 26028054 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 127
Study 23795857 — intervention group
Group type: EXPERIMENTAL
Intervention: CHERRY programme (Choosing Healthy Eating when Really Young)
Number of subjects: 394
Study 23228869 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal artery temperature measurement
Number of subjects: 60
Study 23228869 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal temperature measurement
Number of subjects: 60
Study 23228869 — intervention group
Group type: COMPARATOR
Intervention: Axillary temperature measurement
Number of subjects: 60
Study 20716996 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline infection with STIs (chlamydial, gonococcal, or trichomonal)
Number of subjects: 0
Study 20716996 — intervention group
Group type: COMPARATOR
Intervention: No STIs at baseline
Number of subjects: 0
Study 17569681 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shocks
Number of subjects: 44
Study 17569681 — intervention group
Group type: COMPARATOR
Intervention: Monophasic shocks
Number of subjects: 44
Study 17569681 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (biphasic and monophasic)
Number of subjects: 44
Study 16291467 — intervention group
Group type: EXPERIMENTAL
Intervention: Delphi consensus method
Number of subjects: 154
Study 11899174 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold crystalloid perfusion (4 degrees C Ringer's lactate solution)
Number of subjects: 30
Study 11899174 — intervention group
Group type: COMPARATOR
Intervention: Normothermic blood perfusion
Number of subjects: 30